Paul Mathew

Paul Mathew, M.D.

Assistant Professor of Neurology

617-983-7580

Harvard Catalyst Profile

Faculty Information
Publications

Harvard Title

Assistant Professor of Neurology

Other Affiliations

Brigham and Women's Hospital
Harvard Vanguard Medical Associates

Address

Harvard Vanguard Medical Associates
111 Grossman Dr
Braintree MA 02184

Publications View

A cyclic pain: the pathophysiology and treatment of menstrual migraine.

Authors: Mathew PG, Dun EC, Luo JJ.
Obstet Gynecol Surv 2013-02-01
View full abstract on Pubmed

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

Authors: Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ.
Cancer 2012-01-01
View full abstract on Pubmed

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.

Authors: Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M.
Invest New Drugs 2011-12-01
View full abstract on Pubmed

Taking care of the challenging tension headache patient.

Authors: Mathew PG, Mathew T.
Curr Pain Headache Rep 2011-12-01
View full abstract on Pubmed

Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib.

Authors: Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L.
Cancer Chemother Pharmacol 2011-10-01
View full abstract on Pubmed

Headache.

Authors: Mathew PG, Garza I.
Semin Neurol 2011-02-01
View full abstract on Pubmed

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

Authors: Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.
Clin Cancer Res 2009-11-15
View full abstract on Pubmed

Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.

Authors: Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ.
J Clin Oncol 2009-07-10
View full abstract on Pubmed

Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.

Authors: Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ.
J Clin Oncol 2009-06-10
View full abstract on Pubmed

Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials.

Authors: Vinson J, Mathew P, Beer TM, Carducci MA, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher HI.
J Clin Oncol 2009-05-20
View full abstract on Pubmed